Market Research Logo

Migraine - Pipeline Review, H1 2015

Migraine - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Migraine - Pipeline Review, H1 2015’, provides an overview of the Migraine’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Migraine
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Migraine pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Migraine
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Migraine Overview
Therapeutics Development
Pipeline Products for Migraine - Overview
Pipeline Products for Migraine - Comparative Analysis
Migraine - Therapeutics under Development by Companies
Migraine - Therapeutics under Investigation by Universities/Institutes
Migraine - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Migraine - Products under Development by Companies
Migraine - Products under Investigation by Universities/Institutes
Migraine - Companies Involved in Therapeutics Development
Ache Laboratorios Farmaceuticos S/A
Acorda Therapeutics, Inc.
Alder Biopharmaceuticals Inc.
Allergan, Inc.
Amgen Inc.
Astellas Pharma Inc.
BioDelivery Sciences International, Inc.
Biofrontera AG
Bristol-Myers Squibb Company
Charleston Laboratories, Inc.
CoLucid Pharmaceuticals, Inc.
D-Pharm Ltd.
Dr. Reddy's Laboratories Limited
Eli Lilly and Company
Heptares Therapeutics Limited
iCeutica, Inc.
Mallinckrodt Plc
Medestea Research & Production S.p.A.
Merck & Co., Inc.
Monosol Rx, LLC
NAL Pharmaceuticals Ltd.
Nektar Therapeutics
NeurAxon, Inc.
Northern Light Pharmaceuticals AB
Noxxon Pharma AG
Otsuka Holdings Co., Ltd.
Paladin Labs Inc.
Pantarhei Bioscience BV
Pivot Pharmaceuticals Inc
Pozen, Inc.
RedHill Biopharma Ltd.
Revance Therapeutics, Inc.
Shin Nippon Biomedical Laboratories, Ltd.
Suda Ltd
Teva Pharmaceutical Industries Limited
TheraJect, Inc.
Trevena, Inc.
Trigemina, Inc.
Vertex Pharmaceuticals Incorporated
Migraine - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(dextromethorphan hydrobromide + quinidine sulfate) - Drug Profile
(naproxen sodium + naratriptan hydrochloride) - Drug Profile
(sumatriptan succinate + naproxen sodium) - Drug Profile
AA-71 - Drug Profile
ALD-403 - Drug Profile
AMG-334 - Drug Profile
BEMA Triptan - Drug Profile
BF-1 - Drug Profile
C-012 - Drug Profile
CLH-1T - Drug Profile
corticotropin - Drug Profile
CVT-427 - Drug Profile
Deina - Drug Profile
DFN-02 - Drug Profile
DFN-11 - Drug Profile
DFP-02 - Drug Profile
dihydroergotamine mesylate - Drug Profile
dihydroergotamine mesylate - Drug Profile
DORA-12 - Drug Profile
DP-VPA - Drug Profile
esterol - Drug Profile
histamine dihydrochloride - Drug Profile
ICE-1209 - Drug Profile
ICE-1210 - Drug Profile
ICE-1211 - Drug Profile
IPX-232 - Drug Profile
ketoprofen - Drug Profile
lasmiditan succinate - Drug Profile
LY-2951742 - Drug Profile
NKTR-192 - Drug Profile
NOXL-41 - Drug Profile
NXN-188 - Drug Profile
NXN-462 - Drug Profile
oxytocin - Drug Profile
P-003 - Drug Profile
picotamide - Drug Profile
Protein to Activate Insulin Like Growth Factor 1 Receptor for Migraine - Drug Profile
Rimegepant sulfate - Drug Profile
rizatriptan benzoate - Drug Profile
rizatriptan benzoate - Drug Profile
rizatriptan benzoate - Drug Profile
RT-001 - Drug Profile
Small Molecule to Antagonize CGRP for Migraine - Drug Profile
Small Molecule to Antagonize CGRP Receptor for Migraine - Drug Profile
Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile
Small Molecule to Inhibit nNOS/NET for Migraine and Neuropathic Pain - Drug Profile
Small Molecule to Inhibit Prostaglandin E2 for Pain - Drug Profile
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile
Small Molecules to Inhibit CGRP Receptor for Migraine - Drug Profile
Small Molecules to Inhibit Nitric Oxide Synthase for CNS Disorders - Drug Profile
SST-8055 - Drug Profile
sumatriptan succinate - Drug Profile
sumatriptan succinate - Drug Profile
sumatriptan succinate - Drug Profile
sumatriptan succinate - Drug Profile
TEV-48125 - Drug Profile
Tribarcina - Drug Profile
TRV-250 - Drug Profile
zolmitriptan - Drug Profile
zolmitriptan - Drug Profile
Migraine - Recent Pipeline Updates
Migraine - Dormant Projects
Migraine - Discontinued Products
Migraine - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Migraine, H1 2015
Number of Products under Development for Migraine - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2015
Migraine - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2015
Migraine - Pipeline by Acorda Therapeutics, Inc., H1 2015
Migraine - Pipeline by Alder Biopharmaceuticals Inc., H1 2015
Migraine - Pipeline by Allergan, Inc., H1 2015
Migraine - Pipeline by Amgen Inc., H1 2015
Migraine - Pipeline by Astellas Pharma Inc., H1 2015
Migraine - Pipeline by BioDelivery Sciences International, Inc., H1 2015
Migraine - Pipeline by Biofrontera AG, H1 2015
Migraine - Pipeline by Bristol-Myers Squibb Company, H1 2015
Migraine - Pipeline by Charleston Laboratories, Inc., H1 2015
Migraine - Pipeline by CoLucid Pharmaceuticals, Inc., H1 2015
Migraine - Pipeline by D-Pharm Ltd., H1 2015
Migraine - Pipeline by Dr. Reddy's Laboratories Limited, H1 2015
Migraine - Pipeline by Eli Lilly and Company, H1 2015
Migraine - Pipeline by Heptares Therapeutics Limited, H1 2015
Migraine - Pipeline by iCeutica, Inc., H1 2015
Migraine - Pipeline by Mallinckrodt Plc, H1 2015
Migraine - Pipeline by Medestea Research & Production S.p.A., H1 2015
Migraine - Pipeline by Merck & Co., Inc., H1 2015
Migraine - Pipeline by Monosol Rx, LLC, H1 2015
Migraine - Pipeline by NAL Pharmaceuticals Ltd., H1 2015
Migraine - Pipeline by Nektar Therapeutics, H1 2015
Migraine - Pipeline by NeurAxon, Inc., H1 2015
Migraine - Pipeline by Northern Light Pharmaceuticals AB, H1 2015
Migraine - Pipeline by Noxxon Pharma AG, H1 2015
Migraine - Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Migraine - Pipeline by Paladin Labs Inc., H1 2015
Migraine - Pipeline by Pantarhei Bioscience BV, H1 2015
Migraine - Pipeline by Pivot Pharmaceuticals Inc, H1 2015
Migraine - Pipeline by Pozen, Inc., H1 2015
Migraine - Pipeline by RedHill Biopharma Ltd., H1 2015
Migraine - Pipeline by Revance Therapeutics, Inc., H1 2015
Migraine - Pipeline by Shin Nippon Biomedical Laboratories, Ltd., H1 2015
Migraine - Pipeline by Suda Ltd, H1 2015
Migraine - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015
Migraine - Pipeline by TheraJect, Inc., H1 2015
Migraine - Pipeline by Trevena, Inc., H1 2015
Migraine - Pipeline by Trigemina, Inc., H1 2015
Migraine - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Migraine Therapeutics - Recent Pipeline Updates, H1 2015
Migraine - Dormant Projects, H1 2015
Migraine - Dormant Projects (Contd..1), H1 2015
Migraine - Dormant Projects (Contd..2), H1 2015
Migraine - Dormant Projects (Contd..3), H1 2015
Migraine - Dormant Projects (Contd..4), H1 2015
Migraine - Dormant Projects (Contd..5), H1 2015
Migraine - Discontinued Products, H1 2015
Migraine - Discontinued Products (Contd..1), H1 2015
List of Figures
Number of Products under Development for Migraine, H1 2015
Number of Products under Development for Migraine - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report